Review Article
Updates in Drug Development Strategies against Peptic ulcer
BB Subudhi1*, SP Sahoo2 and PK Sahu1
1School of pharmaceutical Science, Siksha O Anusandhan University, Bhubaneswar, Orissa, 751003, India
2Research Center-II, Aurobindo Pharma Limited, Hyderabad, India
- Corresponding Author:
- BB Subudhi
Associate Professor, Siksha O Anusandhan University School of Pharmaceutical Sciences
School of Pharmaceutical Sciences, Ghatikia, Kalinganagar, Bhubaneswar, 751003, India
Tel: 919853945363
E-mail: bharatbhusans@gmail.com
Received Date: September 16, 2015 Accepted Date: February 26, 2016 Published Date: March 4, 2016
Citation: Subudhi BB, Sahoo SP, Sahu PK (2016) Updates in Drug Development Strategies against Peptic ulcer. J Gastrointest Dig Syst 6:398. doi:10.4172/2161-069X.1000398
Copyright: © 2016 Subudhi BB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Traditional use of antacids and use of histamine inhibitors have become ineffective in the management of peptic ulcer. Irreversible inhibition of proton pump although reduces ulceration, in the long run leads to adverse issues. It has not been possible to develop an ideal proton pump inhibitor. In this scenario, search for alternatives by capitalizing on the multifactorial etiology of ulceration holds promise.
